![](/img/cover-not-exists.png)
FDA Approval Summary: Alpelisib plus fulvestrant for patients with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer
Narayan, Preeti, Prowell, Tatiana M., Gao, Jennifer J, Fernandes, Laura L., Li, Emily, Jiang, Xiling, Qiu, Junshan, Fan, Jianghong, Song, Pengfei, Yu, Jingyu, Zhang, Xinyuan, King-Kallimanis, BellindaJournal:
Clinical Cancer Research
DOI:
10.1158/1078-0432.CCR-20-3652
Date:
November, 2020
File:
PDF, 1.19 MB
2020